p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy

被引:0
|
作者
Cheng, L
Sebo, TJ
Cheville, JC
Pisansky, TM
Slezak, J
Bergstralh, EJ
Pacelli, A
Neumann, RM
Zincke, H
Bostwick, DG
机构
[1] Indiana Univ, Sch Med, Dept Pathol UH 3465, Indianapolis, IN 46202 USA
[2] Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA
[5] Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA
关键词
prostate; protein p53; Ki-67; antigen; glutathione S-transferase; recurrent cancer; radiotherapy;
D O I
10.1002/(SICI)1097-0142(19990315)85:6<1293::AID-CNCR11>3.3.CO;2-F
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The biologic changes in recurrent prostate carcinoma following radiation therapy are not fully understood. The authors sought to determine the level of p53 protein overexpression and its association with cellular proliferation (Ki-67 labeling index), glutathione S-transferase-pi (GST-pi) expression, and other clinical pathologic findings in patients with locally persistent prostate carcinoma after radiation therapy. METHODS. The authors investigated p53 nuclear accumulation, cellular proliferation activity (Ki-67 labeling index by digital image analysis), and GST-pi expression in 55 patients with persistent or recurrent prostate carcinoma after radiation therapy. All patients underwent salvage radical prostatectomy and bilateral pelvic lymphadenectomy following irradiation failure. The interval from radiation therapy to cancer recurrence ranged from 6 months to 17 years (mean, 3.8 years). Age at surgery ranged from 51 to 78 years (mean, 65 years). Mean follow-up after surgery was 5.7 years (range, 1-13 years). RESULTS. p53 protein overexpression was associated with increased cell proliferation (Spearman rank correlation coefficient = 0.29, P = 0.03). A substantial proportion (62%) of recurrent cancer also showed GST-pi immunoreactivity. No apparent correlation was observed between p53 protein overexpression, cellular proliferation (Ki-67 labeling index), or GST-pi expression and Gleason score, pathologic stage, DNA ploidy, or patient outcome. There was an inverse correlation between GST-P expression and Gleason score (P = 0.06). The majority of prostate carcinomas (95%) were proliferative (mean Ki-67 labeling index, 7.0; range, 0-20), whereas concurrent prostatic intraepithelial neoplasia (PIN) had a lower Ki-67 labeling index (mean, 3.1; range, 0-11.5). Nineteen of 28 (68%) concurrent PIN demonstrated p53 immunoreactivity. A trend toward adverse clinical outcome was observed in patients with a higher Ki-67 labeling index in recurrent cancer. CONCLUSIONS. In this study cohort selected for salvage prostatectomy, recurrent cancers were biologically aggressive following radiation therapy. Whether this represents selective persistence and regrowth of prognostically unfavorable tumor clonogens or stepwise clonogenic progression is uncertain. Further investigation is needed to elucidate the correlation between p53 overexpression and the presence of other biologic changes after radiation therapy. Cancer 1999;85:1293-9. (C) 1999 American Cancer Society.
引用
收藏
页码:1293 / 1299
页数:7
相关论文
共 50 条
  • [41] p53 autoantibodies in sera of breast cancer patients: Association with p53 gene mutations and p53 protein overexpression.
    Angelopoulou, K
    Yu, H
    Diamandis, EP
    CLINICAL CHEMISTRY, 1997, 43 : 770 - 770
  • [42] p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma
    H. Moch
    G. Sauter
    T. C. Gasser
    N. Buchholz
    L. Bubendorf
    J. Richter
    F. Jiang
    A. Dellas
    M. J. Mihatsch
    Urological Research, 1997, 25 : S25 - S30
  • [43] Overexpression of p53 in tall cell variants of papillary thyroid carcinoma
    Ruter, A
    Dreifus, J
    Jones, M
    Nishiyama, R
    Lennquist, S
    SURGERY, 1996, 120 (06) : 1046 - 1050
  • [44] p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
    Angelopoulou, K
    Yu, H
    Bharaj, B
    Giai, M
    Diamandis, EP
    CLINICAL BIOCHEMISTRY, 2000, 33 (01) : 53 - 62
  • [45] Increased vascular cell apoptosis and proliferation after balloon injury in p53 null mice
    Matter, CM
    Dantas, MFV
    Ma, L
    Hofmann, E
    Ha, SW
    Lüscher, F
    EUROPEAN HEART JOURNAL, 2002, 23 : 676 - 676
  • [46] Circulating anti p53 antibodies, TP53 gene mutation analysis overexpression of p53 protein in esophageal squamous cell carcinoma (ESCC).
    Metges, JP
    Giroux, MA
    Volant, A
    Morin, JF
    Ferec, C
    Nousbaum, JB
    Labat, JP
    Gouerou, H
    Robaszkiewicz, M
    GASTROENTEROLOGY, 1997, 112 (04) : A614 - A614
  • [47] p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
    Hernandez, L
    Fest, T
    Cazorla, M
    TeruyaFeldstein, J
    Bosch, F
    Peinado, MA
    Piris, MA
    Montserrat, E
    Cardesa, A
    Jaffe, ES
    Campo, E
    Raffeld, M
    BLOOD, 1996, 87 (08) : 3351 - 3359
  • [48] p53 overexpression and cell proliferation as prognostic markers in head and neck cancer
    Girod, SC
    Leitner, I
    Fischer, U
    Junk, M
    Krueger, GRF
    HEAD AND NECK CANCER - ADVANCES IN BASIC RESEARCH, 1996, 1114 : 321 - 325
  • [49] P53 ANTIONCOGENE PRODUCT (P53) OVEREXPRESSION IN TISSUE AND SERUM OF THE PATIENTS WITH HEPATOCELLULAR-CARCINOMA (HCC)
    NAKASHIO, R
    SUEMORI, S
    KIRA, S
    KITAMOTO, M
    KAWAGUCHI, M
    KIMURA, S
    NAKANISHI, T
    KAJIYAMA, G
    GASTROENTEROLOGY, 1993, 104 (04) : A962 - A962
  • [50] p53 expression in locally advanced pharyngeal squamous cell carcinoma
    Lassaletta, L
    Brandáriz, JA
    Benito, A
    de la Cruz, J
    Gómez, C
    Ballestín, C
    Hitt, R
    Colomer, R
    Alvarez-Vicent, JJ
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (12) : 1356 - 1359